This Article Abstract Full Text (PDF) All Versions of this Article: 91/9/845    most recent 01.RES.0000040420.17366.2Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cho, A. Articles by Reidy, M. A. Search for Related Content PubMed PubMed Citation Articles by Cho, A. Articles by Reidy, M. A. Related Collections Genetically altered mice Smooth muscle proliferation and differentiation

(Circulation Research. 2002;91:845.)
© 2002 American Heart Association, Inc.

Integrative Physiology

Matrix Metalloproteinase-9 Is Necessary for the Regulation of Smooth Muscle Cell Replication and Migration After Arterial Injury

Aesim Cho, Michael A. Reidy

From the Department of Pathology, University of Washington, Seattle.

Correspondence to Aesim Cho, PhD, Department of Pathology, Box 357335, University of Washington, 1959 NE Pacific St, Seattle, WA 98026. E-mail ascho{at}u.washington.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Matrix metalloproteinases (MMPs) and, in particular, MMP-9 are important for smooth muscle cell (SMC) migration into the intima. In this study, we sought to determine whether MMP-9 is critical for SMC migration and for the formation of a neointima by using mice in which the gene was deleted (MMP-9^-/- mice). A denuding injury to the arteries of wild-type mice promoted the migration of medial SMCs into the neointima at 6 days, and a large neointimal lesion was observed after 28 days. In wild-type arteries, medial SMC replication was 8% at day 4, 6% at day 6, and 4% at day 8 and had further decreased to 1% at day 14. Intimal cell replication was 65% at 8 days and had decreased to 10% at 14 days after injury. In MMP-9^-/- arteries, SMC replication was significantly lower at day 8. In addition, SMC migration and arterial lesion growth were significantly impaired in MMP-9^-/- arteries. SMCs, isolated from MMP-9^-/- mouse arteries, showed an impairment of migration and replication in vitro. Thus, our present data indicate that MMP-9 is critical for the development of arterial lesions by regulating both SMC migration and proliferation.

Key Words: matrix metalloproteinase-9 • mouse arterial injury • smooth muscle cell replication • migration • neointimal formation

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Arterial lesion growth is an important process in the development of atherosclerosis, restenosis, and vascular graft stenosis. Multiple events participate in this process, including smooth muscle cell (SMC) replication and SMC migration. The importance of SMC migration is often neglected because in most mammalian arteries, there is no obvious way to recognize the movement of SMCs within the artery. However, the migration of SMCs can be studied in the arteries of small mammals because the intima is composed of just the endothelial monolayer, and in these circumstances, the migration of SMCs to the intima can be evaluated.

The migration of SMCs is thought to be regulated by proteases such as plasminogen/plasmin and matrix metalloproteinases (MMPs). Both classes of enzymes are expressed by SMCs, and their expression is markedly upregulated in injured arteries; these arteries invariably develop a pronounced thickened neointima.¹ Plasminogen activators convert the inactive plasminogen to plasmin, which in turn can activate latent MMPs.² Supporting data that plasmin can regulate SMC migration are given in studies in which the deletion of genes encoding for urokinase plasminogen activator or plasminogen resulted in a smaller intimal lesion size in injured mouse arteries.^3,4 There are also convincing data that MMPs are necessary for the migration of SMCs into the intima. The deletion of tissue inhibitor of metalloproteinases (TIMP)-1 in mice leads to the formation of larger intimal lesions in injured arteries, whereas overexpression of TIMP-2 by adenovirus-mediated transfer leads to a temporary reduction in lesion size in injured rat arteries.^5,6 Similar data were obtained when a synthetic MMP inhibitor was administered to rats subjected to arterial injury.^1,7,8 These arteries showed a significant reduction in the size of the early developing neointima. A concern with both of these approaches is that the inhibitors used are not specific. The synthetic MMP inhibitor used by Bendeck et al⁸ is capable of blocking all MMPs, whereas both TIMP-1 and TIMP-2 can affect the activity of many MMPs. As such, it has not been not possible to link a specific MMP with SMC migration and neointimal formation.

Denudation of rat arteries with a balloon catheter leads to an early increase in MMP-9 expression (within 12 hours), accompanied with a later increase in MMP-2 activity.^1,7 The fact that MMP-9 expression occurs before any detected SMC migration into the intima suggests that this MMP might be critical for SMC migration. In the present study, we used MMP-9 null (MMP-9^-/-) mice to determine what role MMP-9 plays in SMC migration and neointimal thickening. Our results show that not only is SMC migration significantly reduced in MMP-9^-/- arteries, but the proliferation of SMC is also impacted. Thus, MMP-9 is a major regulator of neointimal formation.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Animals and Surgical Procedure
MMP-9^-/- mice and wild-type mice (FVB strain) were kindly provided by Dr Zena Werb (University of California, San Francisco). These mouse colonies were bred in our laboratory, and genotypes were verified by polymerase chain reaction analysis. Adult male mice (25 to 35 g) were anesthetized with an intraperitoneal injection of xylazine and ketamine cocktail (0.14 to 0.2 mg xylazine and 2.1 to 3 mg ketamine). Surgery involved a midline incision on the ventral neck, clearing of the connective tissue around the distal portion of the carotid artery, and placement of a suture loop around the external branch of the carotid above the external/internal bifurcation and another loop distal to external branch. A small incision in the external branch between the 2 suture loops (which are used to control blood flow) was made, and a catheter (made from 6-0 nylon suture) was introduced into the carotid. This catheter was advanced to the aortic arch and then withdrawn with rotation. This procedure was repeated 3 times before removing the catheter. Finally, the external branch was tied off using the sutures in place, and the skin incision was closed with wound clips. At various times after injury, the mice were killed by intraperitoneal injections of sodium pentobarbital (Abbott Laboratories), and ice-cold lactated Ringer’s solution was infused retrogradely via the left ventricle of the heart.

Zymography
Tissues were ground to a fine powder and collected into lysis buffer containing 50 mmol/L Tris (pH 7.6, Sigma Chemical Co), 1% SDS (Bio-Rad Laboratories), 1 mmol/L phenylmethylsulfonyl fluoride, and 10 µg/mL leupeptin. The samples were centrifuged, and the supernatant was subjected to zymography according to the procedure previously described by Herron et al.⁹ Total protein (10 µg) from each extract was loaded onto 8% polyacrylamide gels containing 0.1% type I gelatin (Sigma) for MMP activity. After gel electrophoresis, gels were incubated for 16 to 18 hours at 37°C in a buffer (50 mmol/L Tris [pH 8.0], 2.5 mmol/L CaCl₂, and 0.02% sodium azide), rinsed in 10% trichloroacetic acid, and stained in rapid Coomassie stain. The stained gels were visualized by Eagle-Eye Image (Stratagene).

Western Blot Analysis
Arterial tissues were ground to a fine powder and collected into lysis buffer (50 mmol/L sodium pyrophosphate, 50 mmol/L NaF, 50 mmol/L NaCl, 5 mmol/L EDTA, 5 mmol/L EGTA, 2 mmol/L Na₃VO₄, 0.1% Triton X-100, 0.5 mmol/L phenylmethylsulfonyl fluoride, and 10 µg/mL leupeptin in 10 mmol/L HEPES [pH 7.4]). Total protein (10 µg) was loaded onto a 10% SDS-PAGE gel and transferred onto nitrocellulose membranes (PROTRAN, Schleicher & Schuell). Membranes were blocked with 5% nonfat dry milk in TBS-T (10 mmol/L Tris [pH 8.0], 150 mmol/L NaCl, and 0.1% Tween 20), incubated with primary antibody for 1 hour, washed 3 times with TBS-T, incubated with secondary antibody conjugated to horseradish peroxidase (1:1000 dilution) for 1 hour, washed again, and detected by enhanced chemiluminescence. For detection of cyclin D1 and extracellular signal-regulated kinases (ERKs), rabbit polyclonal antibodies raised against cyclin D1 (1:1000 dilution, Santa Cruz, H-295) and ERKs (1:1000 dilution, New England Biolabs Inc), respectively, were used as primary antibodies.

Histology and Immunohistochemistry
Mice were intraperitoneally injected with bromodeoxyuridine (BrdU, 30 µg/g body wt) at 1, 9, and 17 hours before euthanasia. Carotid arteries were perfusion-fixed with 4% paraformaldehyde in PBS for 3 minutes in situ; this was followed by an additional immersion fixation for 20 minutes. Tissues were transferred to 70% alcohol and then processed for paraffin embedding. Each artery was transversely cut in half, and 2 segments were embedded together in a single paraffin block. Histological sections (5 µmol/L in thickness) were cut every 10 sections for staining with hematoxylin and eosin or with Verhoeff-van Gieson. Sections were immunohistochemically stained for smooth muscle -actin (DAKO), macrophages (MOMA-2), and BrdU (Boehringer-Mannheim). Morphometric analysis of cross-sectional areas was performed on arterial sections by using computer-assisted image analysis (NIH image). Hematoxylin-positive (total) and BrdU-positive (replicating) cells were counted on arterial sections (50 to 100 µm apart), and a total of 8 sections per animal were counted.

En Face SMC Migration Assay
Carotid arteries were perfusion-fixed as described above, and the vessels were opened longitudinally and pinned down onto on agar plate with the luminal surface facing upward. Arteries were stained with hematoxylin for 10 seconds and incubated in Scott’s blue for 2 minutes. Migrated SMCs were identified as the hematoxylin-stained cells on the luminal surface of the endothelium-denuded area. The length of the carotid artery was visualized under a microscope at x40 magnification (Nikon), and the total number of migrated SMCs was counted.

Mouse Arterial SMC Isolation
Arterial SMCs were isolated from both FVB wild-type and MMP-9^-/- mouse aortas by an enzyme dispersion approach. Briefly, the aortas were perfused with lactated Ringer’s solution, and the extraneous tissue was stripped off and then incubated in enzyme mix (2 mg/mL BSA, 1 mg/mL collagenase, 0.375 mg/mL soybean trypsin inhibitor, and 0.125 mg/L elastase type III in Hanks’ balanced salt solution) for 30 minutes at 37°C. After incubation, the adventitial layer was carefully removed using watchmaker forceps. The remaining tissue was minced in a fresh enzyme mix and incubated at 37°C for 2 hours. Digested sample was transferred to a centrifuge tube, spun down, resuspended in 10% FBS+DMEM (high glucose), and plated in a tissue culture flask. Cells were allowed to attach and divide for the next several days.

In Vitro Cell Proliferation and Migration Assays
Arterial SMCs were grown to 70% to 80% confluence, serum-starved for 48 hours, and treated with basic fibroblast growth factor (FGF) for 20 hours and then for 2 hours with the addition of [³H]thymidine (1 µCi/mL) at 37°C. After incubation, [³H]thymidine-containing medium was removed, and cold 10% trichloroacetic acid was added for 10 minutes and then washed with fresh 10% trichloroacetic acid. Then 0.5N NaOH was added, and this DNA-containing NaOH solution was transferred into scintillation vials, and the radioactivity was counted. Arterial SMCs were grown to 70% to 80% confluence and then serum-starved as described above. Cells were trypsinized, washed with PBS, and resuspended in the media (DMEM+0.2% BSA). Approximately 1x10⁵ cells were placed in the upper chamber of a 24-well transwell (Costar) precoated with 0.1% type I collagen, and the medium containing platelet-derived growth factor (PDGF, 20 ng/mL) was added to the lower chamber. After 7 hours of incubation, cells on the lower surface were fixed with methanol and stained with hematoxylin. The transwell membranes were cut out, placed on a glass slide with the bottom surfaces of the membranes facing upward, and mounted with Aquamount. Migrated cells on the lower surface of membranes were counted under a microscope at x40 magnification.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Time Course of MMP-9 Activity in Mouse Carotid Artery After Injury
MMP-9 activity was undetectable in uninjured mouse carotid arteries; however, a marked increase in MMP-9 gelatinolytic activity was observed within 4 hours after injury, with maximum activity at 24 hours (Figure 1A). MMP-9 activity was still detectable up to 7 days, but no activity was observed at 14 days after injury. In contrast, MMP-2 was constitutively expressed in uninjured carotid arteries, and its activity did not increase until 4 days and remained elevated up to 14 days after injury (Figure 1A). Thus, the temporal expression of MMP-2 and MMP-9 in injured mouse arteries is similar to the pattern observed in rat carotid arteries.¹ As expected, no MMP-9 activity was detected in MMP-9^-/- arteries, and the gelatinolytic activity of MMP-2 was consistently lower in MMP-9^-/- arteries (Figure 1B).

View larger version (85K): [in this window] [in a new window]   Figure 1. A, Gelatinolytic activity of carotid arteries from wild-type (WT) mice at 0, 4, 24, and 48 hours and at 4, 7, and 14 days after injury. NC indicates normal unmanipulated carotid arteries. B, Gelatinolytic activity of carotid arteries in WT mice and MMP-9-/- (KO) mice at 0, 4, and 24 hours after injury. Carotid arteries were collected at various times after injury and were run on a gelatin zymogram.

Response of Mouse Carotid Arteries to Arterial Injury
The technique used for injuring mouse arteries was different from that previously published; so, first, we documented the growth of the neointima in wild-type mouse arteries after injury with a loop of 6-0 nylon. SMCs were present in the intima by 6 days after injury, and 4 weeks later, a marked thickening of the neointima was observed in wild-type arteries (Figure 2). The intimal lesion showed no evidence of macrophages when it was immunostained with macrophage-specific antibody (data not shown). The intimal thickening in mouse arteries was not concentric and was not observed evenly along the common carotid artery. This is different from the intimal thickening pattern observed in rat arteries, where the lesions are symmetrical.¹

View larger version (78K): [in this window] [in a new window]   Figure 2. Time course of arterial lesion development in mice after injury. a, NC artery of WT mouse. b, Carotid artery at 6 days after injury. c, Carotid artery at 8 days after denudation. Note a few layers of neointimal cells. d, Increased intimal thickening at 14 days after injury. e, Substantial neointimal lesion in WT carotid artery at 28 days after denudation. f, Lack of intimal thickening in KO artery at 28 days after injury. Arrowhead marks internal elastic lamina. Each panel is representative of hematoxylin and eosin staining of arterial sections from 5 to 8 animals per time point.

The neointimal lesion growth was markedly different in MMP-9^-/- mice. Neointimal cells were not detectable in most of the mice examined (5 of 8 mice), and a very small thickening was observed in the remaining mice at 4 weeks after injury (Figure 2f). In contrast, the wild-type arteries had large intimal lesions, which markedly reduced the lumen size (Figure 2e). Both the total number of intimal cells and the intimal area were significantly lower in MMP-9^-/- mouse carotid arteries than in wild-type arteries, whereas the medial cell number and the medial area were not different (Figures 3A and 3B). These results indicate that early expression of MMP-9 after injury is important for the formation of the neointima.

View larger version (26K): [in this window] [in a new window]   Figure 3. Intimal and medial SMC density (A) and area (B) in WT (solid bar) and KO (hatched bar) carotid arteries at 4 weeks after injury. Both the intimal number of cells and the intimal area are significantly lower in KO mice than in WT mice. An unpaired Student t test was used to test for significant differences between the WT and KO arteries. Data are expressed as mean±SEM. *P<0.05 vs WT.

Because MMP-9 can degrade matrix and permit cell migration, we assumed that the difference in the size of the neointima would correlate with a reduced ability of SMCs to migrate into the intima. The SMC migration in MMP-9^-/- and wild-type mice was measured at 6 days after injury by counting the number of luminal cells from en face preparations. This time was chosen because SMCs appeared on the luminal surface at 6 days. Approximately 140 SMCs migrated onto the luminal surface of the wild-type mouse carotid arteries, whereas only 40 cells migrated onto the lumen in MMP-9^-/- arteries (Figures 4A and 4B). Thus, MMP-9 is critical for initial SMC migration into the neointima in injured arteries of mice.

View larger version (82K): [in this window] [in a new window]   Figure 4. A, Photomicrographs showing SMCs that had migrated from the media into the luminal surface of the carotid arteries from WT and MMP-9-/- (KO) mice 6 days after injury. B, Total number of SMCs detected on the luminal surface of carotid artery from WT (solid bar) and MMP-9-/- (MMPKO, hatched bar) mice 6 days after injury. Note the marked reduction in the number of migrated cells in MMPKO arteries compared with WT arteries. An unpaired Student t test was used to test for significant differences between WT and MMPKO arteries. Data are expressed as mean±SEM. *P<0.05 vs WT.

Because the difference in neointimal lesions between wild-type and MMP-9^-/- mice was so large (see Figure 2), we considered the possibility that MMP-9 might affect SMC replication. In wild-type carotid arteries, the medial SMC replication rate reached 8% at 4 days and then gradually decreased to 0.5% at 14 days, and by 4 weeks after injury, no replicating cells were detected (Figure 5A). Intimal SMC replication rate in these arteries was 65% at 8 day but had decreased to 10% at 14 days after injury (Figure 5B). In MMP-9^-/- mouse arteries, the early (4-day) SMC replication was similar to that in the wild-type arteries; however, at 8 days after injury, the cell proliferation rate was significantly lower (4.22±1.10% versus 0.98±0.46%, respectively) (Figure 5A). Similarly, the intimal cell replication rate of MMP-9^-/- arteries was significantly decreased at 8 days after injury (64.7±6.3% for wild-type arteries versus 41.8±6.9% for MMP-9^-/- arteries) (Figure 5B). Furthermore, Western blot analysis showed that cyclin D expression was upregulated at 7 days after injury in wild-type arteries, and this expression was markedly decreased in MMP-9^-/- arteries (Figure 5C). These results suggest that MMP-9 gene expression is important for medial and intimal SMC replication, especially at 8 days after injury, and thus contributes to the development of neointimal lesions.

View larger version (37K): [in this window] [in a new window]   Figure 5. A and B, Medial (A) and intimal (B) cell replication rate in WT (solid bar) and KO (hatched bar) arteries at 4, 6, 8, and 14 days after injury. At 8 days after injury, a significant difference in medial and intimal cell replication rates was observed between WT and KO arteries. An unpaired Student t test was used to test for significant differences between WT and KO arteries. Data are expressed as mean±SEM. *P<0.05 vs WT. C, Western blot (top) showing cyclin D expression in NC arteries and in arteries 7 days after injury (7d) in WT and KO mice. The same blot was reprobed with antibody specific to total ERKs to account for the difference in loading (bottom).

MMP-9^-/- and Wild-Type SMC Migration and Proliferation In Vitro
To further examine the role of MMP-9 on SMC migration and proliferation, we isolated medial SMCs from wild-type and MMP-9^-/- mouse arteries. The isolated cells were immunostained for -actin by using an antibody that is specific for SMC -actin but not for fibroblast -actin. The result showed that almost 100% of the cells were stained positively for SMC -actin (data not shown). An in vitro transwell assay for cell migration showed that wild-type SMCs migrated when PDGF was used as a chemoattractant; however, the migration of MMP-9^-/- cells was significantly attenuated (Figure 6A). Next, we measured cell replication rates by [³H]thymidine incorporation. An 3-fold induction in the replication rate was observed with wild-type SMCs when they were treated with FGF, whereas only a 1.3-fold increase in replication rate was detected with MMP-9^-/- mouse cells (Figure 6B). In accordance with above data, these in vitro studies clearly indicate that MMP-9 is required in the regulation of arterial SMC migration and proliferation.

View larger version (18K): [in this window] [in a new window]   Figure 6. Migration rate (A) and replication rate (B) of cultured SMCs isolated from WT and KO mice. For migration, isolated SMCs were serum-starved for 48 hours, plated onto transwells containing media with or without PDGF (20 ng/mL) in the bottom chamber, and then incubated for 7 hours. Migration experiments were carried out in triplicate and repeated twice. For cell replication, SMCs were serum-starved for 48 hours and treated with FGF2 for 20 hours and then for an additional 2 hours with [3H]thymidine. Experiments were performed in quadruplicate and repeated 3 times. An unpaired Student t test was used to test for significant differences between WT and KO arteries. Data are expressed as mean±SEM. *P<0.05 vs WT+FGF.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In a series of experiments examining neointimal lesion formation in injured rat arteries, it became apparent that the migration of SMCs into the intima was a critical event. Early work focused on the role of plasminogen activators and the formation of plasmin as a necessary protease for SMC migration.^10,11 Recently, we have become interested in the role of MMPs in neointimal growth. Arteries express MMP-9 within hours after injury and continue to do so for up to 7 days, and this is accompanied with an increase in MMP-2 activation.¹ We hypothesized that these MMPs regulate SMC migration, because many metastatic cells express these same proteinases, and we know that SMCs migrate into the intima at times when MMP activity is increased (<7 days). Furthermore, we were able to block SMC migration in injured arteries by the administration of an MMP inhibitor, although the size of the neointimal lesion 14 days after injury was identical to that of injured control arteries.⁸ This occurred despite the daily administration of the MMP inhibitor.

The findings of the present study are that wild-type mouse arteries express MMP-9 after injury and that there is a significant decrease in SMC migration to the intima in MMP-9^-/- arteries. Furthermore, the neointima is significantly smaller in MMP-9^-/- arteries 28 days after injury. These data confirm our hypothesis that MMPs are critical for regulating SMC migration and that MMP-9 has a dominant role. With respect to this latter issue, we did note that MMP-2 activity was reduced in MMP-9^-/- arteries. This fact might suggest that MMP-9 regulates MMP-2 activity directly or indirectly by acting on a certain substrate that can specifically upregulate MMP-2 activity and thus influence SMC migration. Furthermore, because MMP-2 is constitutively expressed in these arteries, changes in MMP-2 activity should occur at the times when MMP-9 is expressed. This is not the case, inasmuch as an increase in MMP-9 was detected by 4 hours, and yet the changes in MMP-2 were not detected until 4 days after injury. We believe that the role of MMP-2 in injured arteries will best be studied by the use of mice with targeted deletion of this gene.

Apart from identifying the critical MMP for SMC migration, these studies also show that a loss of MMP-9 activity can significantly retard neointimal lesion growth. Previous studies in rats and pigs show that MMP inhibition causes only a transient reduction in lesion size and that by 28 days the MMP inhibitor-treated arteries have neointimal lesions equal in size to those of control arteries.^8,12 These results have been used to imply that MMPs do not play a critical role in neointimal lesion growth. We have no explanation as to why inhibition of MMP-9 by pharmacological agents and by gene deletion gives such divergent results. One consideration is that the above-mentioned studies with the MMP inhibitor were carried out in rats and pigs, whereas the present study was in mice. Furthermore, the techniques for injuring arteries in each study were different, although the denuding injuries to rat and mouse arteries appear to elicit similar responses. The pharmacological inhibitor (GM6001) used in these studies has a broad specificity, and one possibility is that this drug interfered with migration in an MMP-independent manner. GM6001 blocks tumor necrosis factor (TNF)--converting-enzyme, which is needed to release TNF- from the cell membrane.¹³ Therefore, one possibility is that the administration of GM6001 not only blocked the activity of MMPs but also downregulated a TNF--induced factor that regulates migration in a negative manner. This event would not occur in mouse arteries with an MMP-9 gene deletion. Finally, there is the possibility that GM6001 does not adequately block MMP-9. The fact that early SMC migration in rats is significantly blocked by GM6001 suggests that the drug is effective; however, in the present study, its chronic administration caused weight loss and diarrhea. Therefore, one consideration is that, over time, this drug is poorly absorbed; thus, MMPs are not effectively blocked at these later times.

A surprising finding in the present study was the significant decrease in medial and intimal SMC replication in MMP-9^-/- arteries 8 days after injury. There are limited data showing that MMPs can regulate cell proliferation. MMP-2 and its association with TIMP-1 and TIMP-2 have been reported to affect the replication of various cells.^14–16 Two recent studies have implicated a link between MMP-9 and cell proliferation. Loss of the MMP-9 gene in K14-HPV16 transgenic mice (overexpressing human papilloma virus) led to reduced keratinocyte hyperproliferation and differentiation,¹⁷ whereas Mohan et al¹⁸ observed an increased epithelial regeneration in the corneas, skin, and tracheas of MMP-9^-/- mice. Using doxycycline, a global MMP inhibitor, Bendeck et al¹⁹ showed that intimal but not medial SMC replication at 7 days was inhibited in injured rat arteries. This latter result matches well with our findings of a decrease in SMC replication that was detected in MMP-9 ^-/- mouse arteries at late (at day 8) but not early times after injury. However, in our experiment, both medial and intimal SMCs were inhibited.

How MMP-9 regulates entry into the cell cycle is unclear. One explanation could be that MMP-9 releases matrix-bound cytokines and growth factors. These might include FGF, vascular endothelial growth factor, transforming growth factor-ß, and TNF-.²⁰ Of these, basic FGF (FGF2) is a likely candidate. Indeed Sasaki et al²¹ reported that NO via activation of MMP-9 and MMP-2 was responsible for the release of FGF2. FGF2 is liberated after injury to arteries and has a well-documented affinity for molecules of the extracellular matrix of arteries.^22,23 Our data in rat injured arteries show that FGF2 is a potent mitogen for SMCs and that its chronic administration induces large intimal lesions.²⁴ Thus, the release of sequestered FGF by MMP-9 might explain the marked difference in SMC replication at 8 days after injury. In wild-type arteries, MMP-9 would be able to free matrix-bound FGF2 and thus stimulate further cell replication, but this would not occur in MMP-9^-/- arteries. By day 14, however, SMC replication in the wild-type arteries is equal to that in the MMP-9^-/- arteries, presumably because at this time MMP-9 activity is downregulated. Alternatively, this could be due to depletion of the pool of extracellular FGF2. We are now examining the possibility that MMP-9 can release matrix-bound FGF2.

Another possible mechanism of how MMP-9 may regulate SMC replication is by disrupting cell-to-cell interactions in injured arteries. A recent study by Ho et al²⁵ showed that overexpression of TIMP-1 or direct inhibition of MMPs upregulates cadherin expression as well as cell-to-cell adhesion in fibroblasts. This was associated with a reduction in the ability of cells to show signs of transformation. Cadherin is a transmembrane glycoprotein that associates with , ß, and catenins. Loss of cadherin from cell membrane releases ß-catenin, which translocates to the nucleus and, in association with the transcription factor, Lef/Tcf, regulates several genes, including cyclin D1.²⁶ Therefore, it is possible that MMP-9 may regulate SMC growth by modulating ß-catenin and cadherin association. We have observed that Lef1 and ß-catenin are highly expressed at times of increased cell proliferation in injured rat arteries. Furthermore, we have preliminary data showing an increased association of ß-catenin with E-cadherin in SMCs isolated from MMP-9^-/- mice (data not shown).

There are reports that other MMPs may regulate intimal lesion growth in mouse arteries. For example, inactivation of the MMP-11 gene was shown to increase neointimal formation and elastin degradation after perivascular electrical arterial injury.²⁷ However, this injury caused little SMC replication but was accompanied with a significant inflammatory response. As such, it is likely that MMP-11 was derived from invading macrophages and was unrelated to SMC migration and replication. In addition, inactivation of the MMP-3 gene was shown to reduce aneurysm formation, but it had no effect on the progression of atherosclerotic lesions in apoE null mice.²⁸ In the present study, neither MMP-3 nor MMP-11 was detected, presumably because of the absence of inflammatory cells; therefore, it is unlikely that they play any role in the formation of neointimal lesions after a denuding injury.

The mice used in the present study were of FVB background strain. This strain forms a large intimal lesion after arterial injury and thus allows us to document the effect of inactivation of the MMP-9 gene in injured arteries. Harmon et al²⁹ reported that compared other mouse strains, FVB mice possess much higher proliferative response to flow-reduced ligation model; in fact, Harmon et al observed large differences in intimal lesion formation between 11 different mice strains. Recent work by Kuhel et al³⁰ has documented that C57Bl/6 mice are resistant to neointimal hyperplasia, whereas FBV/N mice are susceptible to neointimal hyperplasia after arterial injury. In addition, we have preliminary data showing that neointimal formation and SMC replication are greater in FVB mice than in C57Bl/6 mice. Thus, genetic background appears to plays an important role in the formation of intimal lesions, and linkage analysis studies would help to understand the influence of genetic makeup on the arterial tissue response to injury.

In conclusion, we have presented evidence that MMP-9 is critical for the development of neointimal lesions in injured arteries and that MMP-9 contributes to arterial lesion growth by regulating both SMC migration and replication. Thus, MMPs appear to possess multiple functional abilities that are important for vascular tissue remodeling.

	Acknowledgments

 
This study was supported by NIH grants HL-61845 and HL-59908. The authors would like to thank Callie Lowther for technical assistance with mouse surgery and for maintenance of the mouse colony.

Received April 24, 2002; revision received September 23, 2002; accepted September 25, 2002.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994; 75: 539–545.[Abstract/Free Full Text]

2. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991; 78: 3114–3224.[Free Full Text]

3. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997; 99: 200–208.[Medline] [Order article via Infotrieve]

4. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997; 17: 439–444.[CrossRef][Medline] [Order article via Infotrieve]

5. Lijnen HR, Soloway P, Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ Res. 1999; 85: 1186–1191.[Abstract/Free Full Text]

6. Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, Bilato C, Gluzband YA, Crow MT, Stetler-Stevenson W, Capogrossi MC. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 1998; 98: 2195–2201.[Abstract/Free Full Text]

7. Zempo N, Kenagy RD, Au YP, Bendeck MP, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994; 20: 209–217.[Medline] [Order article via Infotrieve]

8. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996; 78: 38–43.[Abstract/Free Full Text]

9. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells, II: expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem. 1986; 26: 2814–2818.

10. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci. 1992; 667: 141–150.[Medline] [Order article via Infotrieve]

11. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 1996; 16: 1373–1382.[Abstract/Free Full Text]

12. de Smet BJ, de Kleijn D, Hanemaaijer R, Verheijen JH, Robertus L, van der Helm YJ, Borst C, Post MJ. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation. 2000; 101: 2962–2967.[Abstract/Free Full Text]

13. Black RA, Rauch CT, Kozloksy CJ, Peschon JJ, Slack JL, Wolfson MF, Caster BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor- from cells. Nature. 1997; 385: 729–733.[CrossRef][Medline] [Order article via Infotrieve]

14. Bello L, Lucini V, Carrabba G, Giussani C, Machluf M, Pluderi M, Nikas D, Zhang J, Tomei G, Villani RM, Carroll RS, Bikfalvi A, Black PM. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res. 2001; 61: 8730–8736.[Abstract/Free Full Text]

15. Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, Lin HC, Friedman SL. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest. 2001; 108: 1369–1378.[CrossRef][Medline] [Order article via Infotrieve]

16. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994; 107: 2373–2379.[Abstract]

17. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000; 103: 481–490.[CrossRef][Medline] [Order article via Infotrieve]

18. Mohan R, Chintala SK, Jung JC, Villar WV, McCabe F, Russo LA, Lee Y, McCarthy BE, Wollenberg KR, Jester JV, Wang M, Welgus HG, Shipley JM, Senior RM, Fini ME. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biol Chem. 2002; 277: 2065–2072.[Abstract/Free Full Text]

19. Bendeck MP, Conte M, Zhang M, Nili N, Strauss HB, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol. 2002; 160: 1089–1095.[Abstract/Free Full Text]

20. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol. 2001; 13: 534–540.[CrossRef][Medline] [Order article via Infotrieve]

21. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem. 1998; 123: 431–439.[Abstract/Free Full Text]

22. Lindner V, Olsen NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries: interaction of heparin with basic fibroblast growth factor. J Clin Invest. 1992; 90: 2044–2049.[Medline] [Order article via Infotrieve]

23. Vigny M, Ollier-Hartmann MP, Lavigne M, Fayein N, Jeanny JC, Laurent M, Courtois Y. Specific binding of basic fibroblast growth factor to basement membrane-like structures and to purified heparan sulfate proteoglycan of the EHS tumor. J Cell Physiol. 1998; 137: 321–328.

24. Olson NE, Chao S, Lindner V, Reidy MA. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am J Pathol. 1992; 140: 1017–1023.[Abstract]

25. Ho AT, Voura EB, Soloway PD, Watson KL, Khokha R. MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function. J Biol Chem. 2001; 276: 40215–40224.[Abstract/Free Full Text]

26. Novak A, Dedhar S. Signaling through ß-catenin and Lef/Tcf. Cell Mol Life Sci. 1999; 56: 523–537.[CrossRef][Medline] [Order article via Infotrieve]

27. Lijnen HR, Van Hoef B, Vanlinthout I, Verstreken M, Rio M-C, Collen D. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler Thromb Vasc Biol. 1999; 19: 2863–2870.[Abstract/Free Full Text]

28. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001; 21: 1440–1445.[Abstract/Free Full Text]

29. Harmon KJ, Couper LL, Lindner V. Strain-dependent vascular remodeling phenotypes in inbred mice. Am J Pathol. 2000; 156: 1742–1748.

30. Kuhel DG, Zhu B, Witte DP, Hui DY. Distinction in genetic determinants for injury-induced neointimal hyperplasia and diet-induced atherosclerosis in inbred mice. Arterioscler Thromb Vasc Biol. 2002; 22: 955–960.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. D. Grabski, T. Shimizu, J. Deou, W. M. Mahoney Jr, M. A. Reidy, and G. Daum Sphingosine-1-Phosphate Receptor-2 Regulates Expression of Smooth Muscle Alpha-Actin After Arterial Injury Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1644 - 1650. [Abstract] [Full Text] [PDF]

				N. Fukai, R. D. Kenagy, L. Chen, L. Gao, G. Daum, and A. W. Clowes Syndecan-1: An Inhibitor of Arterial Smooth Muscle Cell Growth and Intimal Hyperplasia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1356 - 1362. [Abstract] [Full Text] [PDF]

				K. Selvendiran, M. L. Kuppusamy, A. Bratasz, L. Tong, B. K. Rivera, C. Rink, C. K. Sen, T. Kalai, K. Hideg, and P. Kuppusamy Inhibition of Vascular Smooth-Muscle Cell Proliferation and Arterial Restenosis by HO-3867, a Novel Synthetic Curcuminoid, through Up-Regulation of PTEN Expression J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 959 - 966. [Abstract] [Full Text] [PDF]

				L. Wang, J. Zheng, X. Bai, B. Liu, C.-j. Liu, Q. Xu, Y. Zhu, N. Wang, W. Kong, and X. Wang ADAMTS-7 Mediates Vascular Smooth Muscle Cell Migration and Neointima Formation in Balloon-Injured Rat Arteries Circ. Res., March 13, 2009; 104(5): 688 - 698. [Abstract] [Full Text] [PDF]

				D. Pons, F. R. de Vries, P. J. van den Elsen, B. T. Heijmans, P. H.A. Quax, and J. W. Jukema Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease Eur. Heart J., February 1, 2009; 30(3): 266 - 277. [Abstract] [Full Text] [PDF]

				A. Dwivedi, S. C. Slater, and S. J. George MMP-9 and -12 cause N-cadherin shedding and thereby {beta}-catenin signalling and vascular smooth muscle cell proliferation Cardiovasc Res, January 1, 2009; 81(1): 178 - 186. [Abstract] [Full Text] [PDF]

				J. Zhang, L. Nie, M. Razavian, M. Ahmed, L. W. Dobrucki, A. Asadi, D. S. Edwards, M. Azure, A. J. Sinusas, and M. M. Sadeghi Molecular Imaging of Activated Matrix Metalloproteinases in Vascular Remodeling Circulation, November 4, 2008; 118(19): 1953 - 1960. [Abstract] [Full Text] [PDF]

				M. Ogawa, J.-i. Suzuki, K. Hishikari, K. Takayama, H. Tanaka, and M. Isobe Clarithromycin Attenuates Acute and Chronic Rejection Via Matrix Metalloproteinase Suppression in Murine Cardiac Transplantation J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1977 - 1985. [Abstract] [Full Text] [PDF]

				S. Delbosc, M. Glorian, A.-S. Le Port, G. Bereziat, M. Andreani, and I. Limon The Benefit of Docosahexanoic Acid on the Migration of Vascular Smooth Muscle Cells Is Partially Dependent on Notch Regulation of MMP-2/-9 Am. J. Pathol., May 1, 2008; 172(5): 1430 - 1440. [Abstract] [Full Text] [PDF]

				S.-O. Lee, Y.-C. Chang, K. Whang, C.-H. Kim, and I.-S. Lee Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-{alpha}-induced migration of human vascular smooth muscle cells Cardiovasc Res, November 1, 2007; 76(2): 331 - 339. [Abstract] [Full Text] [PDF]

				R. Kadirvel, D. Dai, Y.H. Ding, M.A. Danielson, D.A. Lewis, H.J. Cloft, and D.F. Kallmes Endovascular Treatment of Aneurysms: Healing Mechanisms in a Swine Model Are Associated with Increased Expression of Matrix Metalloproteinases, Vascular Cell Adhesion Molecule-1, and Vascular Endothelial Growth Factor, and Decreased Expression of Tissue Inhibitors of Matrix Metalloproteinases AJNR Am. J. Neuroradiol., May 1, 2007; 28(5): 849 - 856. [Abstract] [Full Text] [PDF]

				D. Segers, F. Helderman, C. Cheng, L. C.A. van Damme, D. Tempel, E. Boersma, P. W. Serruys, R. de Crom, A. F.W. van der Steen, P. Holvoet, et al. Gelatinolytic Activity in Atherosclerotic Plaques Is Highly Localized and Is Associated With Both Macrophages and Smooth Muscle Cells In Vivo Circulation, February 6, 2007; 115(5): 609 - 616. [Abstract] [Full Text] [PDF]

				R. R. Nair, J. Solway, and D. D. Boyd Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression J. Biol. Chem., September 8, 2006; 281(36): 26424 - 26436. [Abstract] [Full Text] [PDF]

				M. M. Kelly, R. Leigh, S. E. Gilpin, E. Cheng, G. E. M. Martin, K. Radford, G. Cox, and J. Gauldie Cell-specific Gene Expression in Patients with Usual Interstitial Pneumonia Am. J. Respir. Crit. Care Med., September 1, 2006; 174(5): 557 - 565. [Abstract] [Full Text] [PDF]

				J. L. Johnson, R. Fritsche-Danielson, M. Behrendt, A. Westin-Eriksson, H. Wennbo, M. Herslof, M. Elebring, S. J. George, W. L. McPheat, and C. L. Jackson Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability Cardiovasc Res, August 1, 2006; 71(3): 586 - 595. [Abstract] [Full Text] [PDF]

				B. Chandrasekar, S. Mummidi, L. Mahimainathan, D. N. Patel, S. R. Bailey, S. Z. Imam, W. C. Greene, and A. J. Valente Interleukin-18-induced Human Coronary Artery Smooth Muscle Cell Migration Is Dependent on NF-{kappa}B- and AP-1-mediated Matrix Metalloproteinase-9 Expression and Is Inhibited by Atorvastatin J. Biol. Chem., June 2, 2006; 281(22): 15099 - 15109. [Abstract] [Full Text] [PDF]

				N. Fiotti, N. Altamura, M. Fisicaro, N. Carraro, L. Uxa, G. Grassi, L. Torelli, R. Gobbato, G. Guarnieri, B. T. Baxter, et al. MMP-9 Microsatellite Polymorphism and Susceptibility to Carotid Arteries Atherosclerosis Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1330 - 1336. [Abstract] [Full Text] [PDF]

				S. Janssens and H. R. Lijnen What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res, February 15, 2006; 69(3): 585 - 594. [Abstract] [Full Text] [PDF]

				J. P.G. Sluijter, D. P.V. de Kleijn, and G. Pasterkamp Vascular remodeling and protease inhibition-bench to bedside Cardiovasc Res, February 15, 2006; 69(3): 595 - 603. [Abstract] [Full Text] [PDF]

				A. C. Newby Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates Cardiovasc Res, February 15, 2006; 69(3): 614 - 624. [Abstract] [Full Text] [PDF]

				Y.-N. Liu, S.-L. Pan, C.-Y. Peng, J.-H. Guh, D.-M. Huang, Y.-L. Chang, C.-H. Lin, H.-C. Pai, S.-C. Kuo, F.-Y. Lee, et al. YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] Inhibits Neointima Formation in Balloon-Injured Rat Carotid through Suppression of Expressions and Activities of Matrix Metalloproteinases 2 and 9 J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 35 - 41. [Abstract] [Full Text] [PDF]

				J. Wei, T. E. Gorman, X. Liu, B. Ith, A. Tseng, Z. Chen, D. I. Simon, M. D. Layne, and S.-F. Yet Increased Neointima Formation in Cysteine-Rich Protein 2-Deficient Mice in Response to Vascular Injury Circ. Res., December 9, 2005; 97(12): 1323 - 1331. [Abstract] [Full Text] [PDF]

				B. Lee and S.-K. Moon Resveratrol Inhibits TNF-{alpha}-Induced Proliferation and Matrix Metalloproteinase Expression in Human Vascular Smooth Muscle Cells J. Nutr., December 1, 2005; 135(12): 2767 - 2773. [Abstract] [Full Text] [PDF]

				A. Ponten, E. Bergsten Folestad, K. Pietras, and U. Eriksson Platelet-Derived Growth Factor D Induces Cardiac Fibrosis and Proliferation of Vascular Smooth Muscle Cells in Heart-Specific Transgenic Mice Circ. Res., November 11, 2005; 97(10): 1036 - 1045. [Abstract] [Full Text] [PDF]

				J. L. Johnson, S. J. George, A. C. Newby, and C. L. Jackson Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries PNAS, October 25, 2005; 102(43): 15575 - 15580. [Abstract] [Full Text] [PDF]

				R. Krams, S. Verheye, L. C.A. van Damme, D. Tempel, B. M. Gourabi, E. Boersma, M. M. Kockx, M. W.M. Knaapen, C. Strijder, G. van Langenhove, et al. In vivo temperature heterogeneity is associated with plaque regions of increased MMP-9 activity Eur. Heart J., October 2, 2005; 26(20): 2200 - 2205. [Abstract] [Full Text] [PDF]

				S. Filippov, G. C. Koenig, T.-H. Chun, K. B. Hotary, I. Ota, T. H. Bugge, J. D. Roberts, W. P. Fay, H. Birkedal-Hansen, K. Holmbeck, et al. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells J. Exp. Med., September 6, 2005; 202(5): 663 - 671. [Abstract] [Full Text] [PDF]

				E. T. Choi, E. T. Collins, L. A. Marine, M. G. Uberti, H. Uchida, J. E. Leidenfrost, M. F. Khan, K. P. Boc, D. R. Abendschein, and W. C. Parks Matrix Metalloproteinase-9 Modulation by Resident Arterial Cells Is Responsible for Injury-Induced Accelerated Atherosclerotic Plaque Development in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1020 - 1025. [Abstract] [Full Text] [PDF]

				A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]

				T. Tazaki, K. Minoguchi, T. Yokoe, K. T. R. Samson, H. Minoguchi, A. Tanaka, Y. Watanabe, and M. Adachi Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1354 - 1359. [Abstract] [Full Text] [PDF]

				R. Kawakami, Y. Saito, I. Kishimoto, M. Harada, K. Kuwahara, N. Takahashi, Y. Nakagawa, M. Nakanishi, K. Tanimoto, S. Usami, et al. Overexpression of Brain Natriuretic Peptide Facilitates Neutrophil Infiltration and Cardiac Matrix Metalloproteinase-9 Expression After Acute Myocardial Infarction Circulation, November 23, 2004; 110(21): 3306 - 3312. [Abstract] [Full Text] [PDF]

				S. M. Lessner, D. E. Martinson, and Z. S. Galis Compensatory Vascular Remodeling During Atherosclerotic Lesion Growth Depends on Matrix Metalloproteinase-9 Activity Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2123 - 2129. [Abstract] [Full Text] [PDF]

				C. Haug, C. Lenz, F. Diaz, and M. G. Bachem Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1823 - 1829. [Abstract] [Full Text] [PDF]

				S.-K. Moon, H.-M. Kim, Y.-C. Lee, and C.-H. Kim Disialoganglioside (GD3) Synthase Gene Expression Suppresses Vascular Smooth Muscle Cell Responses via the Inhibition of ERK1/2 Phosphorylation, Cell Cycle Progression, and Matrix Metalloproteinase-9 Expression J. Biol. Chem., August 6, 2004; 279(32): 33063 - 33070. [Abstract] [Full Text] [PDF]

				G. K. Owens, M. S. Kumar, and B. R. Wamhoff Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease Physiol Rev, July 1, 2004; 84(3): 767 - 801. [Abstract] [Full Text] [PDF]

				K. M. F. Khan, L. R. Howe, and D. J. Falcone Extracellular Matrix-induced Cyclooxygenase-2 Regulates Macrophage Proteinase Expression J. Biol. Chem., May 21, 2004; 279(21): 22039 - 22046. [Abstract] [Full Text] [PDF]

				C. Whatling, W. McPheat, and E. Hurt-Camejo Matrix Management: Assigning Different Roles for MMP-2 and MMP-9 in Vascular Remodeling Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 10 - 11. [Full Text] [PDF]

				R.P. Mason, P. Marche, and T.H. Hintze Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists: Ancillary Actions of Amlodipine Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2155 - 2163. [Abstract] [Full Text] [PDF]

				V. A. Korshunov and B. C. Berk Flow-Induced Vascular Remodeling in the Mouse: A Model for Carotid Intima-Media Thickening Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2185 - 2191. [Abstract] [Full Text] [PDF]

				A. M. Taylor and C. A. McNamara Regulation of Vascular Smooth Muscle Cell Growth: Targeting the Final Common Pathway Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1717 - 1720. [Full Text] [PDF]

				M. M. Islam, C. D. Franco, D. W. Courtman, and M. P. Bendeck A Nonantibiotic Chemically Modified Tetracycline (CMT-3) Inhibits Intimal Thickening Am. J. Pathol., October 1, 2003; 163(4): 1557 - 1566. [Abstract] [Full Text] [PDF]

				M. Kuzuya, S. Kanda, T. Sasaki, N. Tamaya-Mori, X. W. Cheng, T. Itoh, S. Itohara, and A. Iguchi Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia Circulation, September 16, 2003; 108(11): 1375 - 1381. [Abstract] [Full Text] [PDF]

				Z. Luan, A. J. Chase, and A. C. Newby Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 769 - 775. [Abstract] [Full Text] [PDF]

				K. E. Bornfeldt The Cyclin-Dependent Kinase Pathway Moves Forward Circ. Res., March 7, 2003; 92(4): 345 - 347. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 91/9/845    most recent 01.RES.0000040420.17366.2Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cho, A. Articles by Reidy, M. A. Search for Related Content PubMed PubMed Citation Articles by Cho, A. Articles by Reidy, M. A. Related Collections Genetically altered mice Smooth muscle proliferation and differentiation